Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
1.61M
-
Shares change
-
+336K
-
Total reported value, excl. options
-
$20.2M
-
Value change
-
+$4.24M
-
Number of buys
-
20
-
Number of sells
-
-9
-
Price
-
$12.54
Significant Holders of GYRE THERAPEUTICS, INC. - COM (GYRE) as of Q3 2024
38 filings reported holding GYRE - GYRE THERAPEUTICS, INC. - COM as of Q3 2024.
GYRE THERAPEUTICS, INC. - COM (GYRE) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.61M shares
.
Largest 10 shareholders include BlackRock, Inc. (514K shares), VANGUARD GROUP INC (340K shares), GEODE CAPITAL MANAGEMENT, LLC (304K shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (114K shares), STATE STREET CORP (104K shares), NORTHERN TRUST CORP (94.8K shares), Advantage Alpha Capital Partners LP (26.6K shares), GOLDMAN SACHS GROUP INC (18.8K shares), MORGAN STANLEY (18.2K shares), and Bank of New York Mellon Corp (12.5K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.